Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

nazartinib (EGF816)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

sunvozertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

Compound 6a (1)

abivertinib (1)

BAY 2927088 (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

asandeutertinib (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2
EGFR T790M + MET positive	Non Small Cell Lung Cancer	EGFR T790M + MET positive	Non Small Cell Lung Cancer	capmatinib + EGF816 Sensitive: C3 – Early Trials capmatinib + EGF816 Sensitive : C3	capmatinib + EGF816 Sensitive: C3 – Early Trials capmatinib + EGF816 Sensitive : C3